CELU

Celularity Inc CELU

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,828 of 2,925

Why it scores 14Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$5.43M

Quarter to Jun 30

Net income

$706.0K

Quarter to Jun 30

Operating margin

-78.0%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$2.44M total
C V STARR & CO INC
$1.58M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$371.4K0.0%
GEODE CAPITAL MANAGEMENT, LLC
$100.0K-12.5%
CITADEL ADVISORS LLC
$59.2KNew
VANGUARD FIDUCIARY TRUST CO
$47.8K0.0%
BlackRock, Inc.
$45.7K-40.1%
STATE STREET CORP
$34.6K0.0%
HRT FINANCIAL LP
$33.0K+342.7%
NORTHERN TRUST CORP
$26.4K0.0%
Biltmore Family Office, LLC
$20.9K0.0%
HB Wealth Management, LLC
$19.1K-21.0%
KEYNOTE FINANCIAL SERVICES LLC
$17.9K+2.0%
JANE STREET GROUP, LLC
$17.2KNew
CenterStar Asset Management, LLC
$12.9K+17.6%
ROYAL BANK OF CANADA
$11.0K0.0%
Virtu Financial LLC
$11.0KNew
IPG Investment Advisors LLC
$10.3K0.0%
IFP Advisors, Inc
$7.2K+50.0%
Tower Research Capital LLC (TRC)
$3.1K+56.6%
GROUP ONE TRADING, L.P.
$2.1K+3684.2%
WELLS FARGO & COMPANY/MN
$1.5K0.0%
Vanguard Global Advisers, LLC
$1.4K0.0%
SBI Securities Co., Ltd.
$1.4K+25.3%
SIMPLEX TRADING, LLC
$1.3K+3878.2%
UBS Group AG
$1.0K-62.9%
See all 39 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/CELU

Earnings Per Share

13fpro.ai/company/CELU

Loading ratio trend…

CELU key financials by period

Reported revenue, net income and operating margin by fiscal year, from Celularity Inc's annual filings on SEC EDGAR.

Celularity Inc reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$26.6M$-91.7M—
FY 2024$54.2M$-57.9M-70.8%
FY 2023$22.8M$-196.3M—
FY 2022$18.0M$14.2M-142.4%
FY 2021$21.3M$-100.1M—
FY 2020$14.3M$-49.3M-29.6%
Source: CELU filings on SEC EDGAR →

Companies similar to CELU

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

CELU insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Celularity Inc (CELU): stock profile, AI score and financials

Celularity Inc (CELU) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CELU at 14.1/100 on a composite quality score built from its SEC filings, placing it at rank #2,828 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (1.7) and revenue scale (3.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Celularity Inc reports quarterly revenue of $5.4M, net income of $706.0K, an operating margin of -78.0%. Top institutional holders of CELU by reported 13-F value include C V STARR, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. CELU trades on the Nasdaq exchange and files with the SEC under CIK 1752828. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CELU daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Celularity Inc directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1752828 →